Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Makoto Nishio, Shunichi Sugawara, Shinji Atagi, Hiroaki Akamatsu, Hiroshi Sakai, Isamu Okamoto, Koichi Takayama, Hidetoshi Hayashi, Yuki Nakagawa, Tomohisa Kawakami

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.

Original languageEnglish
Pages (from-to)469-476.e1
JournalClinical Lung Cancer
Volume20
Issue number6
DOIs
Publication statusPublished - Nov 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)'. Together they form a unique fingerprint.

Cite this